BIIB

$186.26+3.01 (+1.64%)

Market OpenAs of Mar 17, 7:20 PM UTC

Biogen Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$186.26
Potential Downside
8%
Whystock Fair Value$171.41
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers - General

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$27.34B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
21.17
Beta
Defensive asset. Lower volatility than the S&P 500.
0.14
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
7.39%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.70

Recent News

Simply Wall St.
Mar 17, 2026

Biogen (BIIB) Valuation Check As New SMA Data And Phase 3 Plans Draw Fresh Growth Focus

Biogen (BIIB) has put fresh attention on its spinal muscular atrophy pipeline after sharing new Phase 1b salanersen data showing sustained neurodegeneration biomarker reductions and motor milestone gains, along with detailed plans for three Phase 3 studies. See our latest analysis for Biogen. Against this backdrop of fresh SMA data, Biogen’s share price has moved to US$183.26, with a 6.86% 90 day share price return and a 27.67% 1 year total shareholder return, while longer term total...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 15, 2026

Denali Therapeutics Teases April 5 FDA Decision for Tivi as Launch Plans and Pipeline Catalysts Build

Denali Therapeutics (NASDAQ:DNLI) executives outlined near-term regulatory milestones, commercial launch preparations, and a broadening pipeline during a discussion hosted by Leerink Partners analyst Marc Goodman. Chief Executive Officer Ryan Watts and Chief Commercial Officer Katie Peng focused on

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 13, 2026

Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment

This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Motley Fool
Mar 13, 2026

Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned

This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
MarketBeat
Mar 13, 2026

Biogen Details West Coast Hub, Felzartamab Phase 3 Plans and AMR Readout Timeline at Conference

Biogen (NASDAQ:BIIB) outlined its growing “West Coast Hub” and development plans for felzartamab, an anti-CD38 antibody being studied across multiple kidney-related immunology indications, during a conference discussion between Leerink Partners analyst Marc Goodman and Utpal Patel, Biogen’s Head of

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.